Arkolith/Insider Trading/AVBP/Form 4

Gordon Carl L

Director, 10% OwnerArriVent Biopharma, Inc. (AVBP) · full profile →Form 4 · filed Jan 31, 2024
Net Buying
Open-Market Buys
$8.0M
Open-Market Sells
$0
Net Open-Market Flow
$8.0M
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2024Conversion(C)470K——1.3M
Jan 30, 2024Buy(P)222K$18.00$4.0M1.5M
Jan 30, 2024Conversion(C)470K——1.3M
Jan 30, 2024Conversion(C)822K——822K
Jan 30, 2024Conversion(C)822K——822K
Jan 30, 2024Buy(P)222K$18.00$4.0M1.5M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2024Conversion(C)470K——0
Jan 30, 2024Conversion(C)822K——0
Jan 30, 2024Conversion(C)470K——0
Jan 30, 2024Conversion(C)822K——0

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-008797) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML